Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01113112 · ClinicalTrials.gov registry record
Biobehavioral-Cytokine Interactions in Ovarian Cancer
A clinical trial of Ovarian Neoplasms, sponsored by Susan Lutgendorf.
- Completed
- Registry status
- 613
- Enrollment target
- 2
- Study locations
NCT01113112: Completed study of Ovarian Neoplasms, sponsored by Susan Lutgendorf.
NCT01113112 is a study of Ovarian Neoplasms that has completed, run by Susan Lutgendorf. The registered enrollment target is 613 participants, above the 352-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (74% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01113112, a study of Ovarian Neoplasms, has completed, sponsored by Susan Lutgendorf.
- COMPLETED
- Registry status
- 613 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to understand relationships between behavioral factors, hormones, and chemicals produced by the body that may help tumor growth in ovarian cancer.
Primary Outcome
Pathways by which biobehavioral factors contribute to a permissive local environment for macrophage-tumor interactions that enhance tumor growth in ovarian cancer
Conditions Studied
Study Locations (2)
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 613 participants |
| Start Date | 2003-08 |
| Est. Completion | 2026-01-02 |
What the finished NCT01113112 record still lists
NCT01113112 is an observational study that tracks outcomes without assigning an intervention. The registered 613 participants enrollment target is mid-sized for trials with a published cap, above the 352-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (74% higher).
The record links to 1 condition, with Ovarian Neoplasms appearing as the primary indexed condition, and to 0 interventions.
NCT01113112 reports a single indexed study location in Iowa, Missouri.
Frequently Asked Questions
What is clinical trial NCT01113112 about?
NCT01113112 is a clinical study titled "Biobehavioral-Cytokine Interactions in Ovarian Cancer". The purpose of this study is to understand relationships between behavioral factors, hormones, and chemicals produced by the body that may help tumor growth in ovarian cancer.
What is the current status of trial NCT01113112?
This trial is currently completed. The enrollment target is 613 participants. The study started on 2003-08. Estimated completion is 2026-01-02.
What conditions does trial NCT01113112 study?
This clinical trial studies the following conditions: Ovarian Neoplasms.
Who is sponsoring clinical trial NCT01113112?
This trial is sponsored by Susan Lutgendorf, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01113112 being conducted?
This trial has 2 study locations across Iowa, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01113112's enrollment target sits among peer trials
613 10th of 38 higher than 29 of 38 other Ovarian Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer
RECRUITING · NA
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase 1
-
Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
RECRUITING
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions
RECRUITING · NA
-
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01810913 · 613 participants · Phase 2
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
- NCT03821857 · 614 participants · Phase 4
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
- NCT05006716 · 614 participants · Phase 1
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
- NCT06170788 · 614 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia